For example, the recent realisation that long-term administration of selective COX-2 inhibitors can detrimentally affect the cardiovascular system, resulting in an increased risk of stroke or cardiac infarction (Fitzgerald, 2004), has dampened the enthusiasm for their extensive use as cancer chemopreventive interventions. Here, PTGS2 is linked to cancer.